Published in J Pharmacol Exp Ther on April 03, 2003
High prevalence of the CYP2B6 516G-->T(*6) variant and effect on the population pharmacokinetics of efavirenz in HIV/AIDS outpatients in Zimbabwe. Eur J Clin Pharmacol (2007) 2.68
Relative activation of human pregnane X receptor versus constitutive androstane receptor defines distinct classes of CYP2B6 and CYP3A4 inducers. J Pharmacol Exp Ther (2006) 2.23
CYP2B6: new insights into a historically overlooked cytochrome P450 isozyme. Curr Drug Metab (2008) 2.06
Dendritic spine injury induced by the 8-hydroxy metabolite of efavirenz. J Pharmacol Exp Ther (2012) 1.79
Interpatient variability in the pharmacokinetics of the HIV non-nucleoside reverse transcriptase inhibitor efavirenz: the effect of gender, race, and CYP2B6 polymorphism. Br J Clin Pharmacol (2006) 1.66
Effect of rifampicin-based antitubercular therapy and the cytochrome P450 2B6 516G>T polymorphism on efavirenz concentrations in adults in South Africa. Antivir Ther (2009) 1.66
Associations between CYP2B6 polymorphisms and pharmacokinetics after a single dose of nevirapine or efavirenz in African americans. J Infect Dis (2009) 1.63
CYP2B6 (c.516G-->T) and CYP2A6 (*9B and/or *17) polymorphisms are independent predictors of efavirenz plasma concentrations in HIV-infected patients. Br J Clin Pharmacol (2009) 1.60
Population pharmacokinetic/pharmacogenetic model for optimization of efavirenz therapy in Caucasian HIV-infected patients. Antimicrob Agents Chemother (2011) 1.56
Genome-wide association study of plasma efavirenz pharmacokinetics in AIDS Clinical Trials Group protocols implicates several CYP2B6 variants. Pharmacogenet Genomics (2012) 1.52
Efavirenz primary and secondary metabolism in vitro and in vivo: identification of novel metabolic pathways and cytochrome P450 2A6 as the principal catalyst of efavirenz 7-hydroxylation. Drug Metab Dispos (2010) 1.50
Glucuronidation of the antiretroviral drug efavirenz by UGT2B7 and an in vitro investigation of drug-drug interaction with zidovudine. Drug Metab Dispos (2009) 1.41
A novel polymorphism in ABCB1 gene, CYP2B6*6 and sex predict single-dose efavirenz population pharmacokinetics in Ugandans. Br J Clin Pharmacol (2009) 1.33
CYP2B6, CYP2A6 and UGT2B7 genetic polymorphisms are predictors of efavirenz mid-dose concentration in HIV-infected patients. AIDS (2009) 1.32
Prevalence of CYP2B6 alleles in malaria-endemic populations of West Africa and Papua New Guinea. Eur J Clin Pharmacol (2006) 1.30
Use of antineoplastic agents in patients with cancer who have HIV/AIDS. Lancet Oncol (2011) 1.30
CYP2B6 983T>C polymorphism is prevalent in West Africa but absent in Papua New Guinea: implications for HIV/AIDS treatment. Br J Clin Pharmacol (2007) 1.25
Pharmacokinetics of efavirenz when co-administered with rifampin in TB/HIV co-infected patients: pharmacogenetic effect of CYP2B6 variation. J Clin Pharmacol (2008) 1.17
Importance of ethnicity, CYP2B6 and ABCB1 genotype for efavirenz pharmacokinetics and treatment outcomes: a parallel-group prospective cohort study in two sub-Saharan Africa populations. PLoS One (2013) 1.17
Pharmacogenetic & pharmacokinetic biomarker for efavirenz based ARV and rifampicin based anti-TB drug induced liver injury in TB-HIV infected patients. PLoS One (2011) 1.17
Frequencies of Cytochrome P450 2B6 and 2C8 Allelic Variants in the Mozambican Population. Malays J Med Sci (2013) 1.16
Pharmacogenetics of cytochrome P450 2B6 (CYP2B6): advances on polymorphisms, mechanisms, and clinical relevance. Front Genet (2013) 1.16
Is the recommended dose of efavirenz optimal in young West African human immunodeficiency virus-infected children? Antimicrob Agents Chemother (2009) 1.14
Presence of the CYP2B6 516G> T polymorphism, increased plasma Efavirenz concentrations and early neuropsychiatric side effects in South African HIV-infected patients. AIDS Res Ther (2010) 1.13
Clinical pharmacokinetic, pharmacodynamic and drug-interaction profile of the integrase inhibitor dolutegravir. Clin Pharmacokinet (2013) 1.12
In vitro cytochrome P450-mediated metabolism of exemestane. Drug Metab Dispos (2010) 1.10
Efavirenz: a decade of clinical experience in the treatment of HIV. J Antimicrob Chemother (2009) 1.09
Model-based approach to characterize efavirenz autoinduction and concurrent enzyme induction with carbamazepine. Antimicrob Agents Chemother (2009) 1.09
Comprehensive in vitro analysis of voriconazole inhibition of eight cytochrome P450 (CYP) enzymes: major effect on CYPs 2B6, 2C9, 2C19, and 3A. Antimicrob Agents Chemother (2008) 1.08
Polymorphic variants of cytochrome P450 2B6 (CYP2B6.4-CYP2B6.9) exhibit altered rates of metabolism for bupropion and efavirenz: a charge-reversal mutation in the K139E variant (CYP2B6.8) impairs formation of a functional cytochrome p450-reductase complex. J Pharmacol Exp Ther (2011) 1.08
Non-nucleoside reverse transcriptase inhibitors: a review on pharmacokinetics, pharmacodynamics, safety and tolerability. J Int AIDS Soc (2013) 1.05
Slow efavirenz metabolism genotype is common in Botswana. J Acquir Immune Defic Syndr (2008) 1.04
Effects of CYP2B6 G516T polymorphisms on plasma efavirenz and nevirapine levels when co-administered with rifampicin in HIV/TB co-infected Thai adults. AIDS Res Ther (2010) 1.04
Mechanism of efavirenz influence on methadone pharmacokinetics and pharmacodynamics. Clin Pharmacol Ther (2012) 1.04
Efavirenz in the therapy of HIV infection. Expert Opin Drug Metab Toxicol (2010) 1.02
Secondary metabolism pathway polymorphisms and plasma efavirenz concentrations in HIV-infected adults with CYP2B6 slow metabolizer genotypes. J Antimicrob Chemother (2014) 1.01
Influence of efavirenz pharmacokinetics and pharmacogenetics on neuropsychological disorders in Ugandan HIV-positive patients with or without tuberculosis: a prospective cohort study. BMC Infect Dis (2013) 1.00
Structural features of cytochromes P450 and ligands that affect drug metabolism as revealed by X-ray crystallography and NMR. Future Med Chem (2010) 0.99
CYP2B6 variants and plasma efavirenz concentrations during antiretroviral therapy in Port-au-Prince, Haiti. J Infect Dis (2009) 0.98
In silico prediction of efavirenz and rifampicin drug-drug interaction considering weight and CYP2B6 phenotype. Br J Clin Pharmacol (2011) 0.98
Effects of the CYP2B6*6 allele on catalytic properties and inhibition of CYP2B6 in vitro: implication for the mechanism of reduced efavirenz metabolism and other CYP2B6 substrates in vivo. Drug Metab Dispos (2012) 0.96
Efavirenz pharmacokinetics during the third trimester of pregnancy and postpartum. J Acquir Immune Defic Syndr (2012) 0.95
Use of a physiologically-based pharmacokinetic model to simulate artemether dose adjustment for overcoming the drug-drug interaction with efavirenz. In Silico Pharmacol (2013) 0.95
Contribution of N-glucuronidation to efavirenz elimination in vivo in the basal and rifampin-induced metabolism of efavirenz. Antimicrob Agents Chemother (2011) 0.94
Structure and function of cytochromes P450 2B: from mechanism-based inactivators to X-ray crystal structures and back. Drug Metab Dispos (2011) 0.94
Worldwide variation in human drug-metabolism enzyme genes CYP2B6 and UGT2B7: implications for HIV/AIDS treatment. Pharmacogenomics (2012) 0.93
Pharmacogenetics of plasma efavirenz exposure in HIV-infected adults and children in South Africa. Br J Clin Pharmacol (2015) 0.93
Chemokine (C-C motif) receptor 5 -2459 genotype in patients receiving highly active antiretroviral therapy: race-specific influence on virologic success. J Infect Dis (2011) 0.93
PharmGKB summary: very important pharmacogene information for cytochrome P-450, family 2, subfamily A, polypeptide 6. Pharmacogenet Genomics (2012) 0.92
CYP2B6*6, CYP2B6*18, Body weight and sex are predictors of efavirenz pharmacokinetics and treatment response: population pharmacokinetic modeling in an HIV/AIDS and TB cohort in Zimbabwe. BMC Pharmacol Toxicol (2015) 0.92
Characterization of human cytochrome P450 enzymes catalyzing domperidone N-dealkylation and hydroxylation in vitro. Br J Clin Pharmacol (2004) 0.91
Biotransformation of the antiretroviral drug etravirine: metabolite identification, reaction phenotyping, and characterization of autoinduction of cytochrome P450-dependent metabolism. Drug Metab Dispos (2012) 0.91
In vitro analysis and quantitative prediction of efavirenz inhibition of eight cytochrome P450 (CYP) enzymes: major effects on CYPs 2B6, 2C8, 2C9 and 2C19. Drug Metab Pharmacokinet (2013) 0.91
Inhibition of drug metabolizing cytochrome P450s by the aromatase inhibitor drug letrozole and its major oxidative metabolite 4,4'-methanol-bisbenzonitrile in vitro. Cancer Chemother Pharmacol (2009) 0.91
Prevalence of poor and rapid metabolizers of drugs metabolized by CYP2B6 in North Indian population residing in Indian national capital territory. Springerplus (2012) 0.89
A review of pharmacological interactions between HIV or hepatitis C virus medications and opioid agonist therapy: implications and management for clinical practice. Expert Rev Clin Pharmacol (2013) 0.89
Pharmacogenetic markers of CYP2B6 associated with efavirenz plasma concentrations in HIV-1 infected Thai adults. Br J Clin Pharmacol (2012) 0.89
Absence seizures associated with efavirenz initiation. Pediatr Infect Dis J (2011) 0.89
Influence of CYP2B6 516G>T polymorphism and interoccasion variability (IOV) on the population pharmacokinetics of efavirenz in HIV-infected South African children. Eur J Clin Pharmacol (2011) 0.89
Molecular characterization of CYP2B6 substrates. Curr Drug Metab (2008) 0.88
Host genetic factors predisposing to HIV-associated neurocognitive disorder. Curr HIV/AIDS Rep (2014) 0.88
CYP2B6*6 genotype and high efavirenz plasma concentration but not nevirapine are associated with low lumefantrine plasma exposure and poor treatment response in HIV-malaria-coinfected patients. Pharmacogenomics J (2015) 0.87
Can therapeutic drug monitoring improve pharmacotherapy of HIV infection in adolescents? Ther Drug Monit (2010) 0.87
Identification and analysis of conserved sequence motifs in cytochrome P450 family 2. Functional and structural role of a motif 187RFDYKD192 in CYP2B enzymes. J Biol Chem (2008) 0.87
Pharmacogenetic-based efavirenz dose modification: suggestions for an African population and the different CYP2B6 genotypes. PLoS One (2014) 0.87
The influence of nevirapine and efavirenz-based anti-retroviral therapy on the pharmacokinetics of lumefantrine and anti-malarial dose recommendation in HIV-malaria co-treatment. Malar J (2015) 0.86
Differential effects of clinically used derivatives and metabolites of artemisinin in the activation of constitutive androstane receptor isoforms. Br J Pharmacol (2012) 0.86
Interactions between alcohol and the antiretroviral medications ritonavir or efavirenz. J Addict Med (2013) 0.86
Safe Treatment of Seizures in the Setting of HIV/AIDS. Curr Treat Options Neurol (2013) 0.86
Optimizing efavirenz treatment: CYP2B6 genotyping or therapeutic drug monitoring? Eur J Clin Pharmacol (2008) 0.85
Induction of CYP2C19 and CYP3A activity following repeated administration of efavirenz in healthy volunteers. Clin Pharmacol Ther (2012) 0.85
Plasma concentrations, efficacy and safety of efavirenz in HIV-infected adults treated for tuberculosis in Cambodia (ANRS 1295-CIPRA KH001 CAMELIA trial). PLoS One (2014) 0.85
The role of metabolites in predicting drug-drug interactions: focus on irreversible cytochrome P450 inhibition. Curr Opin Drug Discov Devel (2010) 0.85
Haplotype structure of CYP2B6 and association with plasma efavirenz concentrations in a Chilean HIV cohort. J Antimicrob Chemother (2010) 0.85
Analysis of clinically relevant substrates of CYP2B6 enzyme by computational methods. J Mol Model (2011) 0.85
Metabolic activation of mifepristone [RU486; 17beta-hydroxy-11beta-(4-dimethylaminophenyl)-17alpha-(1-propynyl)-estra-4,9-dien-3-one] by mammalian cytochromes P450 and the mechanism-based inactivation of human CYP2B6. J Pharmacol Exp Ther (2009) 0.84
Impact of CYP polymorphisms, ethnicity and sex differences in metabolism on dosing strategies: the case of efavirenz. Eur J Clin Pharmacol (2014) 0.84
Didanosine population pharmacokinetics in West African human immunodeficiency virus-infected children administered once-daily tablets in relation to efficacy after one year of treatment. Antimicrob Agents Chemother (2009) 0.84
Genome-wide association study of virologic response with efavirenz-containing or abacavir-containing regimens in AIDS clinical trials group protocols. Pharmacogenet Genomics (2015) 0.84
Once-Daily, Single-Tablet Regimens For the Treatment of HIV-1 Infection. P T (2015) 0.84
Organic carbamates in drug design and medicinal chemistry. J Med Chem (2015) 0.83
Compartmentalization and antiviral effect of efavirenz metabolites in blood plasma, seminal plasma, and cerebrospinal fluid. Drug Metab Dispos (2012) 0.83
A targeted proteomics approach for profiling murine cytochrome P450 expression. J Pharmacol Exp Ther (2014) 0.83
Differential induction of ethanol-metabolizing CYP2E1 and nicotine-metabolizing CYP2B1/2 in rat liver by chronic nicotine treatment and voluntary ethanol intake. Eur J Pharmacol (2009) 0.82
Effects of clopidogrel and itraconazole on the disposition of efavirenz and its hydroxyl metabolites: exploration of a novel CYP2B6 phenotyping index. Br J Clin Pharmacol (2013) 0.82
Human biotransformation of the nonnucleoside reverse transcriptase inhibitor rilpivirine and a cross-species metabolism comparison. Antimicrob Agents Chemother (2013) 0.82
Population pharmacogenetic-based pharmacokinetic modeling of efavirenz, 7-hydroxy- and 8-hydroxyefavirenz. J Clin Pharmacol (2013) 0.82
Thr302 is the site for the covalent modification of human cytochrome P450 2B6 leading to mechanism-based inactivation by tert-butylphenylacetylene. Drug Metab Dispos (2011) 0.82
Pharmacogenomics Implications of Using Herbal Medicinal Plants on African Populations in Health Transition. Pharmaceuticals (Basel) (2015) 0.81
Neuropsychometric correlates of efavirenz pharmacokinetics and pharmacogenetics following a single oral dose. Br J Clin Pharmacol (2013) 0.81
An Expanded Analysis of Pharmacogenetics Determinants of Efavirenz Response that Includes 3'-UTR Single Nucleotide Polymorphisms among Black South African HIV/AIDS Patients. Front Genet (2016) 0.81
Clinical and genetic determinants of plasma nevirapine exposure following an intrapartum dose to prevent mother-to-child HIV transmission. J Infect Dis (2013) 0.81
Functional genetic polymorphisms in CYP2C19 gene in relation to cardiac side effects and treatment dose in a methadone maintenance cohort. OMICS (2013) 0.81
Comprehensive Pharmacokinetic, Pharmacodynamic and Pharmacogenetic Evaluation of Once-Daily Efavirenz 400 and 600 mg in Treatment-Naïve HIV-Infected Patients at 96 Weeks: Results of the ENCORE1 Study. Clin Pharmacokinet (2016) 0.81
Population Pharmacokinetics Analysis To Inform Efavirenz Dosing Recommendations in Pediatric HIV Patients Aged 3 Months to 3 Years. Antimicrob Agents Chemother (2016) 0.81
CYP2B6 pharmacogenetics-based in vitro-in vivo extrapolation of efavirenz clearance by physiologically based pharmacokinetic modeling. Drug Metab Dispos (2013) 0.80
Modest but variable effect of rifampin on steady-state plasma pharmacokinetics of efavirenz in healthy African-American and Caucasian volunteers. Antimicrob Agents Chemother (2011) 0.80
Use of enantiomeric bupropion and hydroxybupropion to assess CYP2B6 activity in glomerular kidney diseases. J Clin Pharmacol (2010) 0.80
Investigation of the mechanisms underlying the differential effects of the K262R mutation of P450 2B6 on catalytic activity. Mol Pharmacol (2008) 0.80
Efavirenz-mediated induction of omeprazole metabolism is CYP2C19 genotype dependent. Pharmacogenomics J (2013) 0.80
Modulation of NF-kappaB-dependent transcription and cell survival by the SIRT1 deacetylase. EMBO J (2004) 11.00
Active tamoxifen metabolite plasma concentrations after coadministration of tamoxifen and the selective serotonin reuptake inhibitor paroxetine. J Natl Cancer Inst (2003) 8.66
Comparison of two methods to detect publication bias in meta-analysis. JAMA (2006) 7.34
Pharmacogenetics of tamoxifen biotransformation is associated with clinical outcomes of efficacy and hot flashes. J Clin Oncol (2005) 6.90
Recommendations for examining and interpreting funnel plot asymmetry in meta-analyses of randomised controlled trials. BMJ (2011) 6.80
CYP2D6 genotype, antidepressant use, and tamoxifen metabolism during adjuvant breast cancer treatment. J Natl Cancer Inst (2005) 5.92
Randomized trial of mediastinal lymph node sampling versus complete lymphadenectomy during pulmonary resection in the patient with N0 or N1 (less than hilar) non-small cell carcinoma: results of the American College of Surgery Oncology Group Z0030 Trial. J Thorac Cardiovasc Surg (2011) 5.14
Quantitative effect of CYP2D6 genotype and inhibitors on tamoxifen metabolism: implication for optimization of breast cancer treatment. Clin Pharmacol Ther (2006) 4.81
The impact of cytochrome P450 2D6 metabolism in women receiving adjuvant tamoxifen. Breast Cancer Res Treat (2006) 4.35
Clinical significance of the cytochrome P450 2C19 genetic polymorphism. Clin Pharmacokinet (2002) 3.95
Comprehensive evaluation of tamoxifen sequential biotransformation by the human cytochrome P450 system in vitro: prominent roles for CYP3A and CYP2D6. J Pharmacol Exp Ther (2004) 3.84
Morbidity and mortality of major pulmonary resections in patients with early-stage lung cancer: initial results of the randomized, prospective ACOSOG Z0030 trial. Ann Thorac Surg (2006) 3.76
Guidelines for the management of chronic kidney disease in HIV-infected patients: recommendations of the HIV Medicine Association of the Infectious Diseases Society of America. Clin Infect Dis (2005) 3.63
Pharmacological characterization of 4-hydroxy-N-desmethyl tamoxifen, a novel active metabolite of tamoxifen. Breast Cancer Res Treat (2004) 3.40
The PHD finger of the chromatin-associated protein ING2 functions as a nuclear phosphoinositide receptor. Cell (2003) 3.36
Patients with elevated liver enzymes are not at higher risk for statin hepatotoxicity. Gastroenterology (2004) 3.27
To RCT or not to RCT: deciding when 'more evidence is needed' for public health policy and practice. J Epidemiol Community Health (2011) 3.26
Significant effect of polymorphisms in CYP2D6 and ABCC2 on clinical outcomes of adjuvant tamoxifen therapy for breast cancer patients. J Clin Oncol (2010) 3.21
Genome-wide associations and functional genomic studies of musculoskeletal adverse events in women receiving aromatase inhibitors. J Clin Oncol (2010) 3.02
How vague is vague? A simulation study of the impact of the use of vague prior distributions in MCMC using WinBUGS. Stat Med (2005) 2.95
Contour-enhanced meta-analysis funnel plots help distinguish publication bias from other causes of asymmetry. J Clin Epidemiol (2008) 2.93
Genotype-guided tamoxifen dosing increases active metabolite exposure in women with reduced CYP2D6 metabolism: a multicenter study. J Clin Oncol (2011) 2.47
Endoxifen (4-hydroxy-N-desmethyl-tamoxifen) has anti-estrogenic effects in breast cancer cells with potency similar to 4-hydroxy-tamoxifen. Cancer Chemother Pharmacol (2005) 2.41
Video-assisted thoracic surgery versus open lobectomy for lung cancer: a secondary analysis of data from the American College of Surgeons Oncology Group Z0030 randomized clinical trial. J Thorac Cardiovasc Surg (2010) 2.31
Monitoring mortality rates in general practice after Shipman. BMJ (2003) 2.26
STS database risk models: predictors of mortality and major morbidity for lung cancer resection. Ann Thorac Surg (2010) 2.25
A systematic review of systematic reviews and meta-analyses of animal experiments with guidelines for reporting. J Environ Sci Health B (2006) 2.23
Pathologic lymph node ratio is a predictor of survival in esophageal cancer. Ann Thorac Surg (2012) 2.20
Composite functional genetic and comedication CYP2D6 activity score in predicting tamoxifen drug exposure among breast cancer patients. J Clin Pharmacol (2010) 2.15
Predicted risk of mortality models: surgeons need to understand limitations of the University HealthSystem Consortium models. J Am Coll Surg (2009) 2.10
Pharmacogenetic testing of CYP2C9 and VKORC1 alleles for warfarin. Genet Med (2008) 2.05
Ten-year experience on 644 patients undergoing single-port (uniportal) video-assisted thoracoscopic surgery. Ann Thorac Surg (2013) 2.01
Pharmacogenomics: challenges and opportunities. Ann Intern Med (2006) 1.96
Special treatment issues in lung cancer: ACCP evidence-based clinical practice guidelines (2nd edition). Chest (2007) 1.94
Occult metastases in lymph nodes predict survival in resectable non-small-cell lung cancer: report of the ACOSOG Z0040 trial. J Clin Oncol (2011) 1.93
Predictors of aromatase inhibitor discontinuation as a result of treatment-emergent symptoms in early-stage breast cancer. J Clin Oncol (2012) 1.91
Factors affecting uptake of childhood immunisation: a Bayesian synthesis of qualitative and quantitative evidence. Lancet (2002) 1.91
Estrogen receptor genotypes influence hot flash prevalence and composite score before and after tamoxifen therapy. J Clin Oncol (2008) 1.91
A genome-wide association study identifies locus at 10q22 associated with clinical outcomes of adjuvant tamoxifen therapy for breast cancer patients in Japanese. Hum Mol Genet (2011) 1.91
Ischemia-reperfusion injury after lung transplantation increases risk of late bronchiolitis obliterans syndrome. Ann Thorac Surg (2002) 1.91
Finding qualitative research: an evaluation of search strategies. BMC Med Res Methodol (2004) 1.89
Mechanism-based inactivation of CYP3A by HIV protease inhibitors. J Pharmacol Exp Ther (2004) 1.89
Impact of CYP2B6 polymorphism on hepatic efavirenz metabolism in vitro. Pharmacogenomics (2007) 1.84
Endoxifen, a secondary metabolite of tamoxifen, and 4-OH-tamoxifen induce similar changes in global gene expression patterns in MCF-7 breast cancer cells. J Pharmacol Exp Ther (2006) 1.84
Performance of the trim and fill method in the presence of publication bias and between-study heterogeneity. Stat Med (2007) 1.83
Germline pharmacogenetics of tamoxifen response: have we learned enough? J Clin Oncol (2007) 1.76
Ineffectiveness of histone deacetylase inhibitors to induce apoptosis involves the transcriptional activation of NF-kappa B through the Akt pathway. J Biol Chem (2003) 1.73
A randomized controlled trial of adaptive ventilation for Cheyne-Stokes breathing in heart failure. Am J Respir Crit Care Med (2003) 1.72
Indinavir impairs endothelial function in healthy HIV-negative men. Am Heart J (2005) 1.71
Functional interdependence at the chromatin level between the MKK6/p38 and IGF1/PI3K/AKT pathways during muscle differentiation. Mol Cell (2007) 1.70
Primary payer status affects mortality for major surgical operations. Ann Surg (2010) 1.69
Breast cancer metastasis suppressor 1 functions as a corepressor by enhancing histone deacetylase 1-mediated deacetylation of RelA/p65 and promoting apoptosis. Mol Cell Biol (2006) 1.68
Hepatic cytochrome P450 2E1 activity in nondiabetic patients with nonalcoholic steatohepatitis. Hepatology (2003) 1.65
VKORC1 polymorphisms, haplotypes and haplotype groups on warfarin dose among African-Americans and European-Americans. Pharmacogenomics (2008) 1.65
The impact of the lung allocation score on short-term transplantation outcomes: a multicenter study. J Thorac Cardiovasc Surg (2007) 1.65
Comparative analysis of showering protocols for mass-casualty decontamination. Prehosp Disaster Med (2010) 1.62
Methodology and reporting of systematic reviews and meta-analyses of observational studies in psychiatric epidemiology: systematic review. Br J Psychiatry (2012) 1.60
Thirty- and ninety-day outcomes after sublobar resection with and without brachytherapy for non-small cell lung cancer: results from a multicenter phase III study. J Thorac Cardiovasc Surg (2011) 1.59
Drug interactions and pharmacogenomics in the treatment of breast cancer and depression. Am J Psychiatry (2008) 1.59
Literature based drug interaction prediction with clinical assessment using electronic medical records: novel myopathy associated drug interactions. PLoS Comput Biol (2012) 1.58
High dose melphalan in the treatment of advanced neuroblastoma: results of a randomised trial (ENSG-1) by the European Neuroblastoma Study Group. Pediatr Blood Cancer (2005) 1.55
Differences in reported esophageal cancer resection outcomes between national clinical and administrative databases. J Thorac Cardiovasc Surg (2012) 1.54
Airflows around oxygen masks: A potential source of infection? Chest (2006) 1.53
Comparative metabolic capabilities of CYP3A4, CYP3A5, and CYP3A7. Drug Metab Dispos (2002) 1.52
Drug interactions with herbal products and grapefruit juice: a conference report. Clin Pharmacol Ther (2004) 1.51
EUS-FNA as the initial diagnostic modality in centrally located primary lung cancers. J Clin Gastroenterol (2007) 1.51
Efavirenz primary and secondary metabolism in vitro and in vivo: identification of novel metabolic pathways and cytochrome P450 2A6 as the principal catalyst of efavirenz 7-hydroxylation. Drug Metab Dispos (2010) 1.50
A systematic review of molecular and biological tumor markers in neuroblastoma. Clin Cancer Res (2004) 1.47
Re: CYP2D6 genotype and tamoxifen response in postmenopausal women with endocrine-responsive breast cancer: the Breast International Group 1-98 trial. J Natl Cancer Inst (2012) 1.46
Intraoperative factors and the risk of respiratory complications after pneumonectomy. Ann Thorac Surg (2011) 1.45
The effect of echinacea (Echinacea purpurea root) on cytochrome P450 activity in vivo. Clin Pharmacol Ther (2004) 1.44
Visualization of PtdIns3P dynamics in living plant cells. Plant J (2006) 1.44
A novel technique for localization and excisional biopsy of small or ill-defined pulmonary lesions. Ann Thorac Surg (2004) 1.43
Exhaled air dispersion distances during noninvasive ventilation via different Respironics face masks. Chest (2009) 1.41
Association of polymorphisms of angiogenesis genes with breast cancer. Breast Cancer Res Treat (2007) 1.41
Flexible parametric models for relative survival, with application in coronary heart disease. Stat Med (2007) 1.40
Evidence synthesis as the key to more coherent and efficient research. BMC Med Res Methodol (2009) 1.39
Reduced methadone clearance during aromatase inhibition. J Clin Psychopharmacol (2012) 1.39
Genotyping for polymorphic drug metabolizing enzymes from paraffin-embedded and immunohistochemically stained tumor samples. Pharmacogenetics (2003) 1.39
The use of systematic reviews when designing studies. Clin Trials (2005) 1.39
Drug-induced QT prolongation in cirrhotic patients with transjugular intrahepatic portosystemic shunt. J Clin Gastroenterol (2011) 1.38
High-level expression of EphA2 receptor tyrosine kinase in prostatic intraepithelial neoplasia. Am J Pathol (2003) 1.35